ABSTRACT
INTRODUCTION
Pain is the most common medicine seeking symptom around the world. In the United States, the annual cost of pain was greater than the annual costs of heart disease ($309 billion), cancer ($243 billion), and diabetes ($188 billion) in 2010 and nearly 30% higher than the combined cost of cancer and diabetes. 1 Rheumatic or musculoskel et al. conditions comprise over 150 diseases and syndromes, which are usually progressive and associated with pain. They can be broadly categorized as joint diseases, physical disability, spinal disorders, and conditions resulting from trauma. Musculoskel et al. conditions are leading causes of morbidity and disability, giving rise to enormous healthcare expenditures and loss of work. Symptomatic OA affects approximately 10% of men and 18% of women over 60 years of age, while RA affects between 0.3 and 1% of adults worldwide. 2 Serious adverse effects of NSAIDs are well understood, being related largely to their underlying mechanisms of action. It has been estimated that 5 to 7% of hospital admissions are related to adverse effects of drugs, and, of these hospitalizations, those that result from gastrointestinal, nervous system, renal, or allergic effects of non-aspirin NSAIDs are responsible for approximately 11 to 12%. 3, 4 NSAIDs like indomethacin, ibuprofen, diclofenac, naproxen, aspirin, causes damaging action upon the stomach and intestine due to their acidic nature. 5 While the selective COX-2 inhibitors cause significant adverse effects in the renal and cardiovascular systems, possibly more serious than those caused by conventional NSAIDs. 6 These payouts in the form of adverse effects can't be justified as they do not cure the disease, instead make the patient dependent on the medicine.
Reviewing scenario mentioned above, need of a pain management protocol other than conventional NSAIDs use arises as an emergent subject, which must be safe as well as economical.
In the recent years, various novel approaches have been given by Ayurveda and Yoga system of RESEARCH ARTICLE medicine [7] [8] [9] [10] still most of them are neither adopted by the doctors nor by the patients. The reason behind this appears to be therapy's long duration protocol as the common mass in today's lifestyle wants effective as well as a fast-acting remedy for their complaint. Although, Ayurvedic texts are filled with various treatment modules including Panchakarma (five bio purificatory measures of Ayurvedic medicine) along with many herbo-mineral drugs which are also proved by various trials 8 to be effective in musculoskeletal disorders still they are not able to provide pain management in a short duration. Again this limitation diverts the patients towards the "pain relieving" NSAIDs. Leech or Hirudo medicinalis, has been historically used in medicine to remove blood from patients. Leech therapy was practiced in ancient India and Greece, and evidence of its use is also present in 18th and 19th centuries in Europe and North America.
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Leech therapy or Jalaukāvacārana, universally accepted around the globe, is an integral part of Ayurvedic medicine especially Panchakarma. Although not directly indicated for pain-management in Ayurveda texts, various studies have identified the presence of analgesic enzymes in leech's saliva 12 that can be effective in pain management in musculoskeletal disorders. Few studies have been done previously on the management of OA of the knee joint by leech therapy. But no comparative study with NSAIDs was found during literature review. Also, there is no study which shows its efficacy in pain management irrespective of the site and pathology involved. This trial was conducted to compare the efficacy of leech application as a substitute to the NSAIDs so that if found effective, leech therapy can be used as the pain management method along with primary treatment of that particular musculoskeletal disorder.
MATERIALS AND METHODS
The present study was a randomized controlled trial conducted at the Panchakarma Department of Rishikul Campus, Uttarakhand Ayurved University, Dehradun. Although, Groups A and C patients were unaware of the intervention, Group B patients were informed about the leech therapy procedure. Total 18 patients fulfilling the inclusion criteria were selected and randomly divided into three groups with six patients in each group. 
Inclusion Criteria
• Patient of either sex, > 30 years of age.
• Patient with history of pain for > 6 months.
• Pain in either of knee joint because of OA/RA/ Gout or any other disease.
• Pain in any other joint along with knee joint due to OA/RA/LBA/Gout. • Patient having difficulty in walking with increased walking time.
• Patient unable to perform a routine activity like bathing, eating, dressing due to pain.
Exclusion Criteria
• Patients < 30 years of age.
• History of pain for < 6 months.
• Number of painful sites/joints = 4 or more.
• Patient with bleeding disorders.
• Patients with uncontrolled diabetes.
• Patient with history of allergy to leeches.
• Patient with a history of incompliance for etoricoxib.
• Pain due to malignancy or some secondary cause.
• Pain due to acute (duration > 6 month old) traumatic injury.
• Infective Joint diseases.
• Pregnant and lactating mothers.
Randomization
Patients were randomly allocated to three groups according to the randomization chart generated by GRAPHPAD online randomization tool.
METHODOLOGY
Selected patients were known cases of either OA/RA/ LBP or Gouty arthritis with primary symptom as pain in knee joint. Pretreatment assessment of the patients was done as per assigned criteria. The patient was not allowed to take any other medication during the period of study.
Following intervention was provided to the patients:
• Group A-Etoricoxib tablet 90 mg (ETROBAX by Ranbaxy Laboratories Ltd.) once a day for nine days in the morning, after breakfast (controlled group).
• Group B-3 sittings of Leech therapy after every three-day interval.
• Group C-250mg sugar tablet twice daily after food (Placebo group).
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Methodology for Leech Therapy
Source of Leeches: All the leeches used in trial were purchased from a reputed biological product supplier, India Biologicals from Agra, UP.
Procedure of Leech Therapy 13
Pūrva Karma
Preparation of the leeches: Before applying on patients, Leeches were first prepared by keeping them in Haridr Jala (turmeric water), prepared by adding few pinches of Haridr Carna in a kidney tray half filled with fresh water. When the leeches became active, i.e., moves very fast in the vessel then they were taken out and transferred into a vessel containing fresh cold water. On every sitting new leeches were used for the procedure.
Preparation of patient:
Patients were given mild Abhyanga (external oleation) followed by Vapa Svedana (steam fomentation) over the painful sites for few minutes to increase the superficial circulation and facilitate the blood-letting. The sites were then then cleaned with dry cotton to remove all the greasiness over the area. After that, patients were made to lie in a comfortable position.
Pradhāna Karma
Pricks by lancet were done near the most tender point for application of leeches at the particular sites. Prepared active leeches were then kept over the oozing blood. When leech started sucking blood, the wet cotton pad was placed over it. On an average, 2-3 leeches of 3-4 inches were used at each painful joint, that used to suck 30-50ml of blood individually. The leeches were applied over/nearby most tender points on the joint/site.
Paścāta Karma
Leech Management: Generally after 30-45 minutes, leech automatically detaches from the site. Haridr Carna was then sprinkled over the leech's anterior sucker (mouth) for inducing vomiting. Sometimes gentle squeezing of the leech was required (from its posterior sucker toward anterior sucker) to expel out the sucked blood. After expelling all the blood from its gut, leech becomes active again and stored in fresh water.
Patient Management
When the leech detaches itself from the site, there occurs a secondary bleeding from the site of bite for 2-4 hours or more. Aatdhauta Ghrita (purified fat) of Vaidyaratnam Oushadhsala, Ollur) was applied over the areas where leaches were applied. A few minutes later, cotton gauze pieces were kept over the bleeding sites with firm pressure to absorb the secondary bleeding. When the cotton gauze piece got attached to the site forming a clot, the patient was advised not to unplug it before next day morning to avoid any bleeding.
In a few patients, tight compression bandages were also used to check the bleeding.
Assessment Criteria
Assessment of the patients was done based on the difference in symptomatic score and functional improvement (a) Symptomatic Score:
• Pain assessment was done based on visual analog score (VAS) ranging from 1-10 graded by the patient only.
• Tenderness was graded on the basis of ritchie articular index: Evaluation was done on Day 0 (before the initiation of intervention), on 9th day (completion of intervention) and on 15th day.
Statistical Analysis
The obtained results were subjected to various tests. On all subjective parameters, a paired t-test was applied within groups, and intergroup comparison was done using ANOVA. A p-value less than 0.05 is considered as statistically significant in this study.
Observations
As per demographic data obtained in 18 patients (Table 1) , the mean age was 53.89 ± 7.15 years. Average height was 165.11 cms with an SD of ± 5.06 cms while average weight was 69.5 ± 6.81 kg.
Out of 18, 55.56% were females. 50% were of VataKapha Prakruti while remaining 27.78% and 22.22% were of Vata-Pitta and Pitta-Kapha Prakruti respectively (Table  2) .
About 44.44% were having three joints involved. In 38.89%, two joints were involved while in 16.67% only one knee joint was involved. In 27.78% patients, bilateral knee joints were involved while in 22.22%, vertebral joints were involved (Table 3) .
About 44.44% of patients were having chronicity of the pain for more than 5 years while 38.89% were having the pain from last 2-5 years. Sixty one point eleven percent were taking analgesics once daily while 33.33% were taking twice a day (Table 4) . 
RESULTS
Interventions were given in all three groups from Day 1 to Day 9. An assessment was done before initiation of trial (Day 0) and on completion of the trial (Day 9). While another assessment was done on Day 15 (follow-up assessment) to assess the residual effects of intervention and relapse of symptoms. Pain, assessed according to VAS, was significantly reduced in both groups A and B on the 9th day, i.e., completion of the intervention. Group A showed 79.17% decrease in VAS score while Group B showed a reduction of 66.67%. Group C showed an insignificant drop of 13.2%. The difference between the Group A and Group B was not significant while the difference between the Group B and C, and Group A and C was extremely significant (p < 0.001) ( Tables 5 and 6 ). Six days after intervention completion, i.e., on 15th day, Group A VAS score showed only a 6.25% reduction from the baseline (before treatment) score while group C only a 3.77% reduction from baseline score but both were insignificant statistically. On the other hand, Group B showed an extremely significant (p < 0.001) decrease in pain i.e. of 62.5% from baseline score before the intervention (Tables 7 and 8) .
After 9th day of treatment, tenderness was significantly reduced to 88.89% in both Groups A and B. While in Group C there was in insignificant reduction of 16.67%. The difference in the results of Groups A and B was an insignificant while the percentage difference between Groups B and C, and Groups A and C were highly significant (p < 0.01) ( Tables 5 and 6) .
On 15th assessment, only Group B showed the consistent result with a significant reduction of 66.67% (p < 0.05) from the baseline score. Groups A, C showed insignificant minor changes of 11.11% and 8.33% respectively in tenderness when compared with baseline tenderness grading. (Tables 7 and 8 ) These results when compared to each other showed that the differences were significant in between Groups A, B and Groups B and C.
On 9th day assessment, both Groups A and B showed a significant reduction of 61.64 and 51.92% in WOMAC score, respectively. But the WOMAC score reduction of 5.78% in Group C was not significant.
Although the results obtained in Group A were marginally better than Group B but were not found to be significant when tested statistically. However, the result of both Group A and B, when compared with Group C, were found to be extremely significant (p < 0.001) ( Tables  5 and 6 ).
In 15th day assessment also, mean WOMAC score of Group A showed a steep increase, i.e., only 2.4% drop when compared with baseline score which was insignifi-JRAS cant statistically. A similar pattern was seen in Group C, where the mean WOMAC score was reduced by 4.44% only which may have occurred due to chance. But, Group B WOMAC score remained almost consistent with a drop of 50.97% in comparison to baseline score, even after withdrawal of medicine and this result was found to be significantly better than group A and C when tested statistically (p < 0.001) ( Tables 7 and 8 ).
For functional assessment, walking time was recorded. On the last day of intervention, Groups A and Groups B showed a significant (p < 0.05) reduction of 43.32 and 42.46% respectively, in 20 m walking time. However, the results of both groups differ insignificantly. Group C showed an insignificant reduction of 4.42% and the results were significantly (< 0.001) less when compared with the other two groups (Tables 5 and 6 ). Even the 15th day, Group B showed a significant (p < 0.05) improvement of 37.90% in walking time. While Groups A, C showed a fall in improvement after withdrawal of intervention, as the improvement in walking time reduced to 1.38 and 0.88% respectively, which was statistically insignificant when compared with baseline score and in-between. When results obtained in Group B was compared to Groups A, C it was found to be extremely significant (p < 0.001) ( Tables 7 and 8 ).
Adverse Drug Reaction
Despite normal BT/CT, in two-three patients oozing didn't check even on the next day after Leech therapy. However tight compression bandage along with Sphatikā Carna application was done on the next day which checked the bleeding after a few hours. No other adverse drug reaction (ADR) was found during the course of treatment in both the groups.
DISCUSSION
As the pain was the primary inclusion criteria for this study, the majority of the patients who got registered in the study were suffering from either osteoarthritis or Rheumatoid arthritis involving at least one knee joint.
Results obtained during the period of intervention were only marginally better in the patients who got treated with Etoricoxib in comparison to the patients who were given leech therapy as an intervention.
But the difference was not significant when tested statistically.
On the 15th day of assessment, Pain reduction was consistent in patients treated with leech therapy while on intervention withdrawal, the pain worsened again in the patients who were given Etoricoxib. Also according to the modern science, leech application not only remove blood from that site but also injects biologically active substances which help to manage various ailments. It injects anti-inflammatory, analgesic, and bacteriostatic substances like hirudin, hyaluronidase, histamine like vasodilators, Inhibitors of kallikrein, superoxide production and poorly characterized anesthetics and analgesic compounds with its saliva which can be helpful in subsiding inflammation and pain. 16 These substances might reach deeper tissue zones and possibly the joint spaces. Various bioactive substances in leech saliva may also be as pharmacologically potent as hirudin and thus exert substantial effects in peri-articular tissue and adjacent structure. 17 A study has proven that leech application causes a significant increase in superficial skin perfusion, especially 16 mm around the biting zone. 18 Therefore, it can be assumed that reason for the improvement in pain and inflammation might be a regional analgesic and antiphlogistic effect by these substances enforced by hyaluronidase. Also the antinociceptive effect may also be assumed responsible for pain relief, although no proven justification is available till now. As after bite, biologically active substances present in leech saliva enters the superficial blood, further reaching deep tissues and joint spaces. Hyaluronidase present in leech saliva further facilitates the penetration and diffusion of these substances into the tissues. Due to this enzyme, it is highly probable that the antiphlogistic substances in leech saliva can penetrate deep enough to exert significant effects on periarticular myofascial structures and perhaps even on intra-articular structures. 19 Removal of venous congestion can be another assumption regarding mode of action of Leech therapy. As after leech bite following primary suction of blood by a leech, secondary oozing occurs of a few minutes to hours. This primary sucking and passive-oozing phase of leech therapy decreases venous congestion in the joints. In addition to this, a broad number of anticoagulant agents decrease venous congestion such as the thrombin inhibitor hirudin, apyrase, collagenase, hyaluronidase, Factor Xa inhibitor and fibrinase one and two. 20, 21 This theory also justifies the process of Srotoāodhana by Leech therapy as discussed earlier.
Secondary bleeding for a few minutes to hours, due to hirudin, causes the removal of toxins along with increased circulation to that particular area. A healthy cell gets sick when it is deprived of needed oxygen and nutrition and is unable to remove toxins accumulated during metabolism. Biologically active substances in leech saliva help the cells to absorb necessary nutrition and eliminate toxins.
CONCLUSION
Present work was a pilot study conducted with very small sample size. Still, it suggests that leech application reduces the pain to a significant level and improves quality of life of the patient without any ill effect. More large sampled trials are required to justify these results. Although, based on this study it can't be concluded that leech therapy can replace the primary treatment of RA or OA as per modern or ayurvedic texts because clinician should aim for the treatment of the main pathology instead of treating a particular symptom. But leech therapy can be a substitute for overused NSAIDs, and it can be accompanied either with herbal/herbo-mineral drugs and Panchakarma therapy or with modern medicines.
